Hot on the heels of the latest complete response letter from the US Food and Drug Administration over its AVT02 proposed rival to Humira (adalimumab), biosimilars specialist Alvotech has appointed a new chief quality officer, just six months after the last replacement.
In October, Alvotech announced the appointment of Sarah Tanksley as chief quality officer, replacing Reem Malki who stepped down “for...




